Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation

Tithi Roy, Samuel T. Boateng, Sergette Banang-Mbeumi, Pankaj K. Singh, Pratik Basnet, Roxane Cherille N. Chamcheu, Federico Ladu, Isabel Chauvin, Vladimir S. Spiegelman, Ronald A. Hill, Konstantin G. Kousoulas, Bolni Marius Nagalo, Anthony L. Walker, Jean Fotie, Siva Murru, Mario Sechi, Jean Christopher Chamcheu

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


This article contains supplemental datasets of the recently published related research article “Synthesis, Inverse Docking-Assisted Identification and in vitro Biological Characterization of Flavonol-based Analogs of Fisetin as c-Kit, CDK2 and mTOR Inhibitors against Melanoma and Non-melanoma Skin Cancers” by Roy et al., [1]. It provides in-depth data not included in the original co-submission on the biophysical, molecular docking, and biological characterization of newly synthesized flavonol-based analogs of fisetin, a natural dietary small molecule with anticancer and anti-inflammatory properties. These synthetic small molecules were investigated as new, potential single and/or multi-kinase inhibitors of the cyclin-dependent kinase-2 (CDK2), receptor tyrosine kinases (c-KITs), and mammalian targets of rapamycin (mTOR) targets, potentially active against melanoma or non-melanoma skin cancers. Furthermore, this data-in-brief article comprises additional sets of results on several aspects of the properties of the dual and multiple kinase inhibitor compounds’ effects that were not presented in the associated article, including the activated targets that are dysregulated in skin cancers; the effects on markers of apoptosis; on colony formation; and in scratch wound healing assays. The study has identified a panel of novel fisetin analogs that are either single- or multi-kinase inhibitors, which may be further developed as active for the treatment of melanoma and non-melanoma skin cancers. The dataset presented herein will be utilized for additional studies aiming to establish a biological platform to steer for predictive and experimental screening of novel flavonoids and analogs in relevant organoids, humanized animal models and in vivo disease models. The present results should also serve as a key stepping-stone towards enabling target-structure-based design, synthesis and initial testing of novel analogs or derivatives of fisetin. The current study may eventually lead to the development of safe, promising and preclinical candidate entities for treatment of skin and other forms of cancers as well as various other human diseases, which can possibly add to the general armamentarium of promising and safe drugs for health promotion.

Original languageEnglish (US)
Article number106858
JournalData in Brief
StatePublished - Apr 2021

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation'. Together they form a unique fingerprint.

Cite this